Greek pharma industry faces funding gap despite new measures

The Greek pharmaceutical industry is grappling with severe underfunding, as recent government adjustments fall short of resolving a critical hospital drug financing gap.

New figures reveal that in the first half of 2023, pharmaceutical companies covered nearly 83% of the cost of hospital drugs priced over 30 euros ($32).

According to a recent statement by the Hellenic Association of Pharmaceutical Companies (SfEE), only 2.4 out of 10 hospital drugs were funded by the state in 2023, leaving the industry to absorb the remaining costs.